Objectives: This study investigated strategies that may increase the yield of drug resistance testing prior to starting antiretroviral therapy (ART), and whether transmitted and polymorphic resistance-associated mutations (RAMs) correlated with virological outcomes.
Introduction
The double-blinded, placebo-controlled, Phase 2 SENSE (Study of Etravirine Neuropsychiatric Symptoms versus Efavirenz) trial randomized treatment-naive patients from Europe, Israel and Russia to receive either etravirine or efavirenz with two investigatorselected nucleos(t)ide reverse transcriptase inhibitors (NRTIs). 1, 2 At screening, plasma samples were tested by the vircoTYPE w HIV-1 genotypic assay to exclude patients with transmitted drug resistance. Routine genotypic resistance tests employ Sanger sequencing to detect mutants that represent the predominant viral strains in the sample. Mutants present at a frequency below 20% can escape detection, suggesting that a greater proportion of patients may carry resistant mutants than is appreciated by routine methods. The issue is especially relevant to therapy with non-nucleoside reverse transcriptase inhibitors (NNRTIs). 3 Using sensitive methods, low-frequency NNRTI-resistant mutants have been detected in antiretroviral therapy (ART)-naive patients with and without high-frequency mutants, and have been shown to impair responses to NNRTI-based therapy and influence the detection probability and type of NNRTI resistance-associated mutations (RAMs) emerging at the time of failure. 4 -8 We previously employed allele-specific PCR (AS-PCR) to obtain a sensitive assessment of resistance in treatment-naive patients. 4,5,7 -9 These studies showed that the detection of NRTI or NNRTI RAMs by AS-PCR in baseline plasma was predictive of an increased risk of virological failure after starting first-line therapy with two NRTIs plus either efavirenz or nevirapine. 4, 5, 7 Whereas resistance testing by Sanger sequencing is well established in clinical practice and recommended in all new diagnoses of HIV-1, 10 recent observations suggest that sensitive resistance testing by techniques such as AS-PCR or ultra-deep sequencing (UDS) should be adopted routinely for patients due to start NNRTIbased therapy. However, the cost and labour intensity, practicalities of implementation, and complexity of data analysis must be taken into account when formulating recommendations for diagnostic settings. The yield of sensitive resistance testing relative to Sanger sequencing, and the impact on treatment outcomes, may also vary across populations 11 and by methodology, 12 thereby influencing cost-effectiveness. In untreated patients, transmitted drug-resistant mutants that are no longer replicating at a high level may persist as 'archived' resistance within the HIV-1 DNA present in latently infected cells. It remains unclear whether the Sanger sequencing of HIV-1 DNA recovered from peripheral blood mononuclear cells (PBMCs) adds sensitivity to the detection of transmitted drug resistance relative to the Sanger sequencing of plasma HIV-1 RNA. Studies in ART-experienced patients have described different HIV-1 populations in plasma and PBMCs. 13, 14 However, data from ART-naive patients are conflicting. Some studies have detected RAMs more frequently in PBMCs than in plasma, 15 -17 while others have indicated a concordance between the two compartments. 18 -20 The primary aim of this study was to investigate strategies that may increase the detection of resistance prior to starting ART, by comparing the yield of Sanger sequencing of plasma HIV-1 RNA ( plasma SS) with that of: (i) AS-PCR and UDS of baseline plasma; and (ii) Sanger sequencing of HIV-1 DNA recovered from PBMC ( PBMC SS). We then correlated the findings with virological outcomes over 48 weeks of randomized treatment with etravirine or efavirenz plus two NRTIs.
Methods

Study population
In the SENSE trial, 193 subjects were screened and 157 were randomized and treated. The country of origin of the screened and randomized patients is shown in Table 1 . The details of the study design have previously been described.
1,2 Treatment-naive patients were randomized to either etravirine 400 mg once daily (n¼79) or efavirenz 600 mg once daily (n¼78) with two investigator-selected NRTIs (either tenofovir/emtricitabine, abacavir/lamivudine or zidovudine/lamivudine). Etravirine was administered as four 100 mg tablets once daily (or a matching placebo), and efavirenz as a single 600 mg tablet once daily (or a matching placebo). Patients attended at screening, at baseline and at weeks 2, 6, 12, 24, 36 and 48, with a follow-up visit when the study was unblinded.
Written informed consent was obtained from all participants prior to study entry. The trial protocols were reviewed and approved by the institutional ethics committees and health authorities for each participating centre and were undertaken in accordance with the Declaration of Helsinki and Good Clinical Practice. The Data Safety Monitoring Board reviewed the safety data after all patients had completed week 12 or discontinued prematurely and recommended continuation of the trial (ClinicalTrials.gov identifier: NCT00903682).
Resistance testing
Plasma samples collected at screening underwent resistance testing at Virco BVBA (now Janssen Diagnostics BVBA, Beerse, Belgium) using the vircoTYPE w HIV-1 assay, which employs Sanger sequencing. Patients with RAMs in RTor protease (PR) that were part of the Bennett list for the surveillance of transmitted drug resistance 21 were to be excluded from the trial. The presence of polymorphic RAMs that were part of the etravirine genotypic resistance score, but were not included in the Bennett list, was allowed; these included V90I, A98G, K101H, V106I, E138A and V179D/T. 22 -24 Recruited patients underwent repeat testing by vircoTYPE w HIV-1 at the baseline visit. During the trial, plasma samples underwent vircoTYPE w HIV-1 testing at the time of virological failure.
Baseline plasma samples from 157 recruited patients were also tested by AS-PCR as previously described. 4, 5, 9 The AS-PCR targeted the NNRTI RAMs K103N, Y181C and G190A and the NRTI RAM M184V. Samples from patients with subtype B infection were also tested for the presence of the NNRTI RAMs L100I, K101E and Y188L. Mutation-specific interpretative cut-offs ranging from 0.3% to 1% were applied as previously described. 4, 5, 9 A subset of 24 baseline plasma samples also underwent UDS (Janssen Infectious Diseases BVBA, Beerse, Belgium) using the 454 GS FLX platform (454 Life Sciences, Roche, Branford, CT, USA), as previously described. 25 Briefly, viral RNA was extracted from 600 mL of plasma using easyMag (bioMérieux, Durham, NC, USA). RNA was reverse-transcribed and amplified Strategies for drug resistance testing 1091 JAC using the SuperScript III One-Step RT-PCR System with Platinum w Taq DNA Polymerase (Life Technologies, Gent, Belgium). Expand High-Fidelity DNA Polymerase (Roche) was used to amplify a 1.8 kb fragment spanning RT (HXB2 positions 2012 -3879, including RT amino acids 1 -443) during a nested PCR. Pooled PCR products were sheared using a Covaris w E210 system (Covaris, Woburn, MA, USA) to median lengths of 400 bp. The fragmented DNA was repaired and adaptors were ligated using the SPRIworks Fragment Library System II (Beckman Coulter Genomics, Grenoble, France). Fragments were indexed using the GS FLX Titanium Rapid Library MID Adaptors Kit (Roche). Finally, fragments were clonally amplified on capture beads in water-in-oil emulsion micro-reactors, and pyrosequenced using the GS FLX Titanium Sequencing Kit XLR70 (Roche) on both lanes of a two-lane PicoTiterPlate according to the manufacturer's standard protocol. Amplicons were sequenced from both ends (forward and reverse). The CLC bio workbench was used for read-mapping and calculating variant frequencies at each position relative to the HXB2 HIV-1 reference strain. The experiment was designed to reach on average a mutation detection sensitivity of 1%, and an average coverage of 8536 reads per RT positions 1 -400 was obtained. A detection limit of 1% was chosen to avoid the high probability of technical artefacts below this threshold.
12 By means of additional error correction, only variants that occurred for 1% in both sequencing directions were taken into account. A selection of these samples (n¼12/24) was also analysed on the Illumina platform (Illumina, San Diego, CA, USA) with identical results (data not shown).
At baseline, PBMCs were isolated from 91 patients and stored centrally at 2808C. PBMC-derived HIV-1 DNA was tested for the presence of RAMs using Sanger sequencing. Briefly, HIV-1 DNA was recovered from 1-2×10 6 cells per sample using the Qiagen DNA blood mini kit (Qiagen, Manchester, UK) according to the manufacturer's instructions, and the PR (amino acids 1 -99) and RT (amino acids 1 -335) regions of HIV-1 pol were sequenced as previously described, 5, 26 omitting reverse transcription. AS-PCR, UDS and PBMC SS were carried out retrospectively, blinded to the vircoTYPE w HIV-1 results and trial outcomes.
Analysis
The primary endpoint of SENSE was the percentage of patients with ≥1 grade 1 -4 treatment-emergent, drug-related neuropsychiatric adverse event at week 12. Virological responses were compared using the protocoldefined endpoint of time to loss of virological response as previously described. 1,2 Virological suppression was defined as two consecutive viral load levels ,50 copies/mL. Virological failure was defined as: (i) after virological suppression, two consecutive viral load values ≥50 copies/mL (10 -20 days apart); (ii) after virological suppression, discontinuation of treatment with a last observed viral load value on treatment ≥50 copies/ mL; (iii) never achieving virological suppression. For the resistance analysis, transmitted RAMs (tRAMs) were those listed by Bennett et al. 21 with the addition of the RT mutations T215N and E138K. The T215N mutation is thought to arise from viruses that once contained the thymidine analogue mutations (TAMs) T215Y or T215F and to be a marker of transmitted NRTI resistance like other revertant mutants at this codon (e.g. T215C).
27
E138K is a non-polymorphic mutation that is selected commonly by rilpivirine, confers low-level cross-resistance to etravirine and has been included in the revised etravirine genotypic score. 24 Polymorphisms included in the etravirine genotypic score, but not included in the Bennett list, were classified as etravirine RAMs.
Results
Sanger sequencing of plasma samples at study entry Among the 193 screened subjects, 16 (8.3%) showed ≥1 tRAM in plasma using the vircoTYPE w HIV-1 assay (Table 1) . These included 15 patients with tRAMs from the Bennett list, 21 and one patient with the RT mutation T215N. TAMs or  T215 revertants (T215D, T215E, T215C, T215N ) and one patient with the PR mutation L90M (Table 1) . A further 19/193 (9.8%) patients showed etravirine RAMs that were part of the etravirine genotypic score, but were not included in the Bennett list, because these mutations were polymorphic. Overall, 15 patients entered the study with one etravirine RAM comprising V90I (n¼ 6), V106I (n¼ 4) or E138A (n¼ 5); each etravirine RAM was present in isolation.
Sensitive testing of plasma samples at baseline
The characteristics of the randomized population are shown in Table 2 . Baseline plasma samples were retested by the vircoTYPE w HIV-1 assay and the results were identical to those obtained at screening (data not shown). The median HIV-1 RNA load in baseline plasma was 4.8 log 10 copies/mL (range 3.5-6.6 log 10 copies/mL). AS-PCR results were obtained in 152/157 (97%) randomized patients (Table 3) . PCR amplification products were not obtained with five samples from patients infected with HIV-1 CRF_AG (n¼ 3), subtype C and subtype B and showing HIV-1 RNA levels between 3.5 and 5.1 log 10 copies/mL. Overall 54 non-B subtype samples were tested for the NRTI RAM M184V and the NNRTI RAMs K103N, Y181C and G190A; 98 subtype B samples were also tested for the NNRTI RAMs L100I, K101E, and Y188L. Three samples lacking tRAMs by plasma SS showed borderline AS-PCR reactivity for the tRAMs M184V (n¼ 2) and K103N (n¼ 1); this, however, was not confirmed by repeat testing. None of the other samples showed any of the tRAMs targeted by AS-PCR.
A subset of 24 baseline plasma samples also underwent UDS (RTregion 1 -400). These comprised the three samples with preliminary borderline AS-PCR reactivity and a random selection of 21 other samples. With all samples, UDS confirmed plasma SS results (Table 3) . Three patients with RAMs underwent both plasma SS and UDS and the results were identical, including detection of the tRAM T215N (at a frequency of 97% by UDS) in one patient, and the etravirine RAMs V90I (frequency 14%) and E138A (frequency 67%) in two other patients. There were no additional tRAMs or etravirine RAMs. The three samples with preliminary borderline AS-PCR reactivity showed no tRAMs by UDS. (Table 3) . Two mutations were detected only in PBMCs. One patient from Israel (subtype C, plasma HIV-1 RNA load 4.7 log 10 copies/mL) showed the NNRTI tRAM K101E; the mutation was not detected by either plasma SS or UDS (AS-PCR not available). A second patient from Austria (CRF06_cpx, plasma HIV-1 RNA load 4.5 log 10 copies/mL) had the NNRTI tRAM E138K in PBMCs; the mutation was not detected by plasma SS (AS-PCR and UDS not available).
Sanger sequencing of PBMCs at baseline
Virological responses over 48 weeks in patients with tRAMs or etravirine RAMs
Among the 6/157 randomized patients with tRAMs, two discontinued the study drug within 2 weeks due to baseline resistance and adverse events, respectively; four patients were responders at week 48, including the two patients with K101E/K and E138K detected only in PBMCs (Table 4) . Among the 15/157 randomized patients who entered the trial with etravirine RAMs, 11 were randomized to etravirine and 4 to efavirenz. One patient receiving etravirine was lost to follow-up after the baseline visit, whereas one patient receiving efavirenz discontinued on day 2 due to adverse events; the remaining 13 patients (10 on etravirine) were responders at week 48.
Over 48 weeks, 4/79 (5.1%) patients in the etravirine arm experienced virological failure, including two who did not achieve virological suppression and two with virological rebound. None of the patients had baseline tRAMs or etravirine RAMs and none showed emerging RAMs at virological failure. The failure samples showed a viral load ,1000 copies/mL (Figure 1 ). Overall 7/78 (9.0%) patients in the efavirenz arm experienced virological failure over 48 weeks, including four who did not achieve virological suppression and three with virological rebound. None of the patients had baseline tRAMs or etravirine RAMs. At virological failure, three with a viral load of 73, 81 and 10 700 copies/mL, respectively, did not show emerging RAMs by vircoTYPE w HIV-1. One patient with a viral load of 56 copies/mL did not yield a resistance test result. The other three patients showed an emergence of 
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RAMs with the following patterns: V106I + M184I (week 48, viral load 2180 copies/mL); K103N (week 54, viral load 81 600 copies/ mL); and L74I/L +V90I + K103N+ M184V/I/M (week 36, viral load 51 800 copies/mL).
Discussion
This study investigated methods that may increase the detection of resistance in patients undergoing screening prior to starting first-line ART, and analysed the correlation between baseline RAMs and virological outcomes over 48 weeks of randomized treatment with etravirine or efavirenz plus two NRTIs. Relative to Sanger sequencing, sensitive testing by AS-PCR and UDS did not increase the detection of resistance in baseline plasma samples. Comparing the results of Sanger sequencing in baseline plasma and PBMCs, two patients among the 91 tested harboured one RAM in PBMCs but not in plasma. Over 48 weeks, there was a small number of virological failures in both arms and none had baseline RAMs by any method. Conversely, the presence at baseline of singleton V90I, V106I or E138A, which are polymorphic mutations included in the etravirine score, did not have a discernible negative impact on virological responses. We found no increased detection of transmitted drug resistance by AS-PCR in this population. While this may have in part reflected a geographical variability in the transmission of drug resistance, the overall prevalence of tRAMs detected in plasma by Sanger sequencing, at 8.3%, was in line with cohort data reported from the regions that participated in SENSE. 28 -34 Although the prevalence of resistance by drug class and temporal trends vary across cohorts, consistent with our findings the most common tRAMs in published surveys were those affecting the NRTIs (especially TAMs and T215 revertants) and the NNRTIs (especially at codons 103, 181 and 190). The AS-PCR targeted six NNRTI tRAMs, which were chosen based on the previously demonstrated impact of minority NNRTI RAMs on responses to NNRTI-based ART.
3 -8, 35 The AS-PCR also targeted the NRTI tRAM M184V, as the mutant declines rapidly after transmission due to its negative effect on viral fitness, escaping detection by routine testing. 36, 37 Our AS-PCR methodology has been extensively validated and previously shown to increase the detection of NNRTI RAMs relative to Sanger sequencing in both ART-naive and ART-experienced patients.
4,5,9, 35 We also previously demonstrated good concordance between AS-PCR and UDS for the detection of NNRTI RAMs. 35 Here, in a subset of patients, we used UDS covering the whole RT to confirm the findings, without increasing the detection of resistance. Given that not all samples were tested by UDS, it is possible that some less common tRAMs might have been missed. Consistent with our results, however, a recent study reported Geretti et al.
that, among 10 Dutch patients with single NRTI tRAMs detected by Sanger sequencing, no additional tRAMs were found by UDS.
11 In contrast, a previous study by Simen et al. 6 reported that, among 258 patients entering a trial of first-line ART in the USA, 14% and 28% had mutations (including both tRAMs and polymorphic RAMs) by Sanger sequencing and UDS, respectively. We previously compared the yield of Sanger sequencing and AS-PCR in a London cohort that started first-line NNRTI-based ART between 1998 and 2007. 5 Four of 18 patients with virological failure and zero of 75 patients with virological success showed the tRAM K103N by AS-PCR alone. These two previous studies 5, 6 were pooled with eight additional studies that employed sensitive resistance testing, together comprising 985 ART-naive patients across the USA and Western Europe. 7 Overall, low-frequency RAMs (typically K103N) were detected in 187 participants lacking RAMs by Sanger sequencing. These observations indicate that the yield of sensitive resistance testing will vary in different populations of ARTnaive patients. Identifying predictive factors is important. Approximately half of the patients in SENSE were white men who have sex with men (MSM) infected with HIV-1 subtype B, a group commonly found to harbour the highest rates of transmitted drug resistance in Western Europe and North America. 28, 33, 38, 39 In the Simen et al. 6 study, a higher baseline viral load was the only significant difference between patients with and without RAMs by UDS. The median viral load was slightly lower in the SENSE population (4.8 log 10 copies/mL) compared with the Simen et al.
6 study (5.3 -5.5 log 10 copies/mL) and our previous London study (5.2 log 10 copies/mL), 5 and this might have reduced the detection of low-frequency RAMs. In the pooled analysis, patients with lowfrequency RAMs had lower CD4 counts than those in whom these variants were not detected (median, 208 versus 234 cells/mm 3 ). 7 The median CD4 count at the time of testing in SENSE was 296 cells/mm 3 and the mean duration of HIV-1 diagnosis was relatively short (2.7 years). It may therefore be proposed that lowfrequency RAMs are more likely to be detected where sufficient time has elapsed since transmission to allow for the decline of dominant variants. 40 As efforts are made to promote early HIV diagnosis and initiation of ART, the findings imply that, across Europe, a large number of patients would require screening in order to identify the few who are harbouring low-frequency RAMs with a recognized impact on treatment outcomes. This observation implies that the cost-effectiveness of different resistance-testing strategies should be considered both in terms of the likelihood of detection in different populations and the likely impact on virological responses. Different considerations should apply to resistance testing in ART-experienced patients. As the yield of resistance testing is higher in recent compared with established infection, 40 such efforts may improve the detection of transmitted resistance by routine methods. The development of new approaches for UDS that allow a reliable pooled testing of multiple samples can also be explored as a potentially cost-effective option for screening Strategies for drug resistance testing 1095 JAC baseline plasma samples. 41, 42 Besides the recognized impact on NNRTI-based ART, further studies are needed to determine the clinical relevance of low-frequency RAMs on treatment outcomes.
A previous study demonstrated that during primary HIV-1 infection the baseline resistance profile was identical in paired plasma and PBMCs, and as a result of a massive seeding of reservoirs in untreated patients all RAMs persisted in both plasma and PBMCs over 2 years. 19 Some of the transmitted mutants may disappear from the plasma over time 40 while persisting in cellular HIV-1 DNA. 15 -17 We found that the testing of baseline PBMCs detected all the mutants already found in plasma and two additional NNRTI tRAMs in two patients who responded well to therapy. Other studies have reported bidirectional discordances between plasma and PBMC resistance patterns, however, 16, 17 indicating that PBMC testing can be an adjunct to, but not a replacement for, plasma testing. This has cost implications that must be balanced against the modest increase in sensitivity and uncertain clinical impact before recommendations can be made for routine practice.
The relationship between baseline genotype and virological response to etravirine was previously investigated in NNRTI-experienced patients receiving etravirine with an optimized background regimen (including ritonavir-boosted darunavir) within the DUET trials. 22, 23 Seventeen etravirine RAMs (V90I, A98G, L100I, K101E/P/H, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L), each with an assigned weight factor, were included in the etravirine-weighted genotypic score, and weighted mutation scores of 0-2, 2.5-3.5 and ≥4 were found to be predictive of the highest, intermediate or reduced responses, respectively. The score was subsequently extended with three additional mutations (E138G/K/Q). 24 Some of the RAMs included in the etravirine score occur as polymorphisms in ART-naive patients, and it is unknown whether their detection, particularly as singletons, should be a contraindication to the use of etravirine. The presence of such baseline polymorphisms was not an exclusion criterion in SENSE, and 15 patients entered the trial with V90I, V106I or E138A, including 11 patients randomized to etravirine, without any evidence of a negative impact on virological responses. It should be noted that the weight of these mutations is only 1-1.5 in the etravirine score and that the mutations were present in isolation. There are scarce data on the resistance pathways selected by etravirine in previously NNRTI-naive patients. In this trial, only four patients experienced virological failure; all had low HIV-1 RNA levels and none of them showed emerging resistance despite multiple attempts by Sanger sequencing to identify this. While promising, additional studies are warranted to confirm the influence of baseline polymorphisms on etravirine activity and the etravirine genetic barrier in ART-naive patients.
